Feng Xu

US Patent:

6512144, Jan 28, 2003

Filed:

Dec 1, 2000

Appl. No.:

09/728536

Inventors:

Gregory J. Lewis - Mt. Prospect IL
Paula L. Bogdan - Mt. Prospect IL
Feng Xu - Buffalo Grove IL
Joseph A. Kocal - Glenview IL

Assignee:

UOP LLC - Des Plaines IL

International Classification:

C07C 4500

US Classification:

564123, 568 27, 568 28, 568403, 568471, 568476, 568910

Abstract:

Processes for oxidizing hydrocarbons using a new family of crystalline manganese phosphate compositions have been developed. These compositions have an extended network which network can be a one-, two-, or three-dimensional network. The composition has an empirical formula of: where A is a structure directing agent such as an alkali metal, M is a metal such as Al, Fe and âbâ is the average manganese oxidation state and varies from greater than 2. 0 to a maximum of 3. Specific oxidation processes are oxidative dehydrodimerization and oxidative dehydrogenation.

US Patent:

6569461, May 27, 2003

Filed:

Apr 26, 2000

Appl. No.:

09/558800

Inventors:

Richard D. Tillyer - Cranford NJ
Paul J. Reider - Westfield NJ
Edward J. J. Grabowski - Westfield NJ
Feng Xu - Staten Island NY
Jose M. Vega - Trappe PA
Mandana Asgharnejad - Ambler PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 900

US Classification:

424497, 424400, 424464, 424465, 424482, 424490

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.

US Patent:

7009055, Mar 7, 2006

Filed:

Jul 19, 2002

Appl. No.:

10/484610

Inventors:

Feng Xu - Staten Island NY, US
Kimberly A. Savary - Rahway NJ, US
John M. Williams - Hillsborough NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 215/16

US Classification:

546177, 546180, 568 34, 568 28

Abstract:

A dibromomethyl moiety is converted to a sulfonylmethyl moiety by treatment with a sulfinic acid salt. For example, (methyl-sulfonyl)methyl bromo-quinoline is prepared by the treatment of dibromomethyl bromo-quinoline with a sulfinic acid salt.

US Patent:

7339054, Mar 4, 2008

Filed:

Feb 6, 2004

Appl. No.:

10/544575

Inventors:

Feng Xu - Staten Island NY, US
Matthew M Bio - London, GB
Cameron Cowden - Hoddesdon, GB
Kimberly A. Petrillo - Philadelphia PA, US
J. Michael Williams - Hillsborough NJ, US
Chunhua Yang - Edison NJ, US
Marjorie See Waters - Cranbury NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07H 19/14
C07D 487/00

US Classification:

536 2711, 536 272, 544262

Abstract:

A process is provided for the preparation of branched-chain ribonucleosides of formula (I):.

US Patent:

7345214, Mar 18, 2008

Filed:

Oct 3, 2005

Appl. No.:

11/242560

Inventors:

Feng Xu - Buffalo Grove IL, US
Lorenz J. Bauer - Schaumburg IL, US
Ralph D. Gillespie - Gurnee IL, US
Maureen L. Bricker - Buffalo Grove IL, US
Steven A. Bradley - Arlington Heights IL, US

Assignee:

UOP LLC - Des Plaines IL

International Classification:

C07C 4/02
B01J 23/00
B01J 23/42
B01J 21/00
B01J 20/00

US Classification:

585752, 502258, 502261, 502262, 502302, 502303, 502304, 502313, 502314, 502326, 502327, 502332, 502334, 502339, 502349, 502350, 502351, 502355, 502415, 502439

Abstract:

A catalyst for opening naphthenic rings has been developed. The catalyst comprises ruthenium and platinum as the active catalytic metals and a modifier with cerium being a preferred modifier. At least 50% of the platinum and ruthenium components are present as particles wherein more ruthenium is present on the surface of the particles than in the center. All of these components are dispersed on a metal oxide support such as aluminas. A ring opening process using the catalyst is also described.

US Patent:

7902376, Mar 8, 2011

Filed:

Jan 22, 2009

Appl. No.:

12/321533

Inventors:

Feng Xu - Staten Island NY, US
Mary M. Kim - Cheltenham PA, US
Yoshinori Kohmura - Ibaraki, JP
Tricia Sladicka - Schenectady NY, US
Jonathan D. Rosen - Iowa City IA, US
Michael J. Zacuto - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Banyu Pharmaceutical Co., Ltd. - Tokyo

International Classification:

C07D 498/04
C07D 487/04
C07D 309/10

US Classification:

548218, 548242, 5483605, 549419

Abstract:

A novel process is provided for the preparation of chiral trans-2,3-disubstituted 5-oxotetrahydropyrans of structural formula (I):.

US Patent:

8022084, Sep 20, 2011

Filed:

Jan 26, 2006

Appl. No.:

11/813796

Inventors:

Daniel J. Kumke - Rahway NJ, US
Jerry A. Murry - Rahway NJ, US
Bryon L. Simmons - Rahway NJ, US
Feng Xu - Rahway NJ, US

Assignee:

H. Lundbeck A/S - Valby

International Classification:

A61K 31/4355
C07D 498/04

US Classification:

514302, 546116

Abstract:

The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.

US Patent:

8193216, Jun 5, 2012

Filed:

Aug 16, 2011

Appl. No.:

13/210908

Inventors:

Daniel J. Kumke - Colts Neck NJ, US
Jerry A. Murry - Thousand Oaks CA, US
Bryon L. Simmons - Hamilton NJ, US
Feng Xu - Staten Island NY, US

Assignee:

H. Lundbeck A/S - Valby

International Classification:

A61K 31/4355
C07D 498/04

US Classification:

514302, 546116

Abstract:

The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.